PE20030477A1 - ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a - Google Patents

ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a

Info

Publication number
PE20030477A1
PE20030477A1 PE2002001009A PE2002001009A PE20030477A1 PE 20030477 A1 PE20030477 A1 PE 20030477A1 PE 2002001009 A PE2002001009 A PE 2002001009A PE 2002001009 A PE2002001009 A PE 2002001009A PE 20030477 A1 PE20030477 A1 PE 20030477A1
Authority
PE
Peru
Prior art keywords
alkyl
heteroaryl
phenyl
inhibitors
adenosine
Prior art date
Application number
PE2002001009A
Other languages
English (en)
Inventor
Deen Tulshian
Lisa S Silverman
Julius J Matasi
John P Caldwell
Eugenia Y Kiselgof
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20030477A1 publication Critical patent/PE20030477A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

SE REFIERE A 5-AMINO-IMIDAZOLO[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA SUSTITUIDO DE FORMULA I, DONDE: R ES R1-HETEROARILO, R10-FENILO, -C(=CH2)CH3, CH3, -CH=C(CH3)2, OXAZOL; X ES ALQUILENO C1-C6, COCH2, CONR2CH2; Y ES NR2CH2CH2NR3, OCH2CH2NR2, O, S, CH2S, (CH2)(2-3)-NR2, R5-HETEROARILO, GRUPO a, b, c, Z ES R5-FENILO, ALQUILO C1-C6, R5-HETEROARILO, DIFENILMETILO, R6CO, CUANDO Y ES GRUPO c, Z TAMBIEN ES R6-SO2, R7-NR8CO, R7NR8CS, R6OCO; CUANDO Q ES CH, Z ES FENILAMINO, PIRIDILAMINO; Z E Y SON GRUPOS d, e, ENTRE OTROS O Z E Y FORMAN UN ANILLO PIPERIDINILO, PIRROLIDINILO FUSIONADO A ARILO O HETEROARILO MONOCICLO O BICICLO; X ESTA UNIDO AL N DEL PIPERIDINILO, PIRROLIDINILO; R1 ES H, ALQUILO, CF3, HALOGENO, NO2, NR12R13, ALCOXI, ALQUILTIO, ENTRE OTROS; R2 Y R3 SON H, ALQUILO; m Y n SON 2-3; p Y q SON 0-2; Q Y Q1 SON N, CH, C-CN, COH, C-COCH3; POR LO MENOS UNO DE Q Y Q1 ES N, CH; R4 ES H, ALQUILO, R1-ARILO, R1-HETEROARILO; R5 ES H, HALOGENO, ALQUILO, HIDROXI, ALCOXI, CN, ENTRE OTROS; R6 ES ALQUILO C1-C6, R5-FENILO, TIENILO, ENTRE OTROS; R7 ES ALQUILO, R5-FENILO; R8 ES H, ALQUILO C1-C6, R7 Y R8 JUNTOS SON (CH2)p-A-(CH2)q; p Y q SON 2-3; A ES UN ENLACE, CH2, S, O.TAMBIEN SE REFIERE AL USO CON AGENTES L-DOPA, AGONISTAS DOPAMINERGICOS, INHIBIDORES DE MAO-B, INHIBIDORES DE DOPA DECARBOXILASA, INHIBIDORES COMT. LOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL COMO PARKINSON
PE2002001009A 2001-10-15 2002-10-11 ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a PE20030477A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32956701P 2001-10-15 2001-10-15

Publications (1)

Publication Number Publication Date
PE20030477A1 true PE20030477A1 (es) 2003-06-06

Family

ID=23286007

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001009A PE20030477A1 (es) 2001-10-15 2002-10-11 ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a

Country Status (16)

Country Link
US (1) US6653315B2 (es)
EP (1) EP1435960B1 (es)
JP (2) JP4545437B2 (es)
KR (1) KR100687954B1 (es)
CN (1) CN100421663C (es)
AR (1) AR037243A1 (es)
AU (1) AU2002340184B2 (es)
CA (1) CA2463598C (es)
HU (1) HUP0401777A3 (es)
IL (1) IL160878A0 (es)
MX (1) MXPA04003474A (es)
MY (1) MY124864A (es)
NZ (1) NZ531761A (es)
PE (1) PE20030477A1 (es)
WO (1) WO2003032996A1 (es)
ZA (1) ZA200402812B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453836B1 (en) * 2001-11-30 2007-03-28 Schering Corporation BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
CN100415217C (zh) 2002-12-19 2008-09-03 先灵公司 腺苷A2a受体拮抗剂的应用
MY139344A (en) 2003-04-23 2009-09-30 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
BRPI0411120A (pt) * 2003-06-10 2006-07-18 Kyowa Hakko Kogyo Kk método para tratar de um distúrbio de ansiedade, composição, agente para tratar de um distúrbio de ansiedade, e, usos de um composto e de um derivado de xantina
NZ547557A (en) * 2003-12-19 2010-07-30 Schering Corp Pharmaceutical compositions containing a cationic A2A receptor antagonist
US7709492B2 (en) * 2004-04-21 2010-05-04 Schering Corporation Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
ES2385702T3 (es) 2005-06-07 2012-07-30 Kyowa Hakko Kirin Co., Ltd. Antagonistas de A2A para uso en el tratamiento de trastornos de la motricidad
EP1934227B1 (en) 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
PE20070521A1 (es) * 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
WO2008045272A2 (en) * 2006-10-06 2008-04-17 Dynamis Therapeutics, Inc. Compositions and methods for skin lightening
US8835426B2 (en) * 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
EP2183228B1 (en) * 2007-07-26 2014-08-20 Vitae Pharmaceuticals, Inc. CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
WO2009102428A2 (en) * 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
WO2009102460A2 (en) * 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2262811B1 (en) 2008-03-04 2016-04-27 Merck Sharp & Dohme Corp. 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e]-1,2,4-triazolo [4,3-c]pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
US20110105504A1 (en) * 2008-03-18 2011-05-05 Vitae Pharmaceuticals ,Inc. Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1
EP2291370B1 (en) 2008-05-01 2013-11-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5301563B2 (ja) 2008-05-01 2013-09-25 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
CA2723039A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2291373B1 (en) * 2008-05-01 2013-09-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
NZ590495A (en) 2008-07-25 2012-10-26 Vitae Pharmaceuticals Inc Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201016691A (en) 2008-07-25 2010-05-01 Boehringer Ingelheim Int Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2744946A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
KR20120061771A (ko) * 2009-04-30 2012-06-13 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
EP2448928B1 (en) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
AU2011306358B2 (en) * 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
WO2015027431A1 (en) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
CN113329791A (zh) 2018-11-30 2021-08-31 默沙东公司 作为腺苷受体拮抗剂的9-取代的氨基***并喹唑啉衍生物、药物组合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0217748B1 (en) 1985-09-30 1991-02-06 Ciba-Geigy Ag 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof
JPH06104666B2 (ja) 1986-09-30 1994-12-21 チバ―ガイギー アクチェンゲゼルシャフト ２―置換―ｅ―縮合―〔１，２，４〕トリアゾロ〔１，５―ｃ〕ピリミジン類及びそれを含有する医薬組成物
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
WO1995003806A1 (fr) 1993-07-27 1995-02-09 Kyowa Hakko Kogyo Co., Ltd. Remede contre la maladie de parkinson
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
EP1069126B1 (en) * 1998-04-03 2003-05-28 Otsuka Pharmaceutical Factory, Inc. Triazolopurine derivatives, medicinal composition containing the derivatives, adenosine a3 receptor compatibilizing agent, and asthmatic remedy
KR20020046285A (ko) 1999-09-28 2002-06-20 고마즈 교우이찌 트리아조로푸린 유도체,그 유도체를 함유하는 의약 조성물및 아데노신 에이 3 수용체 친화제
ATE293627T1 (de) 2000-05-26 2005-05-15 Schering Corp Adenosin a2a rezeptor antagonisten
DE60234951D1 (de) 2001-11-30 2010-02-11 Schering Corp Adenosin a2a rezeptor antagonisten

Also Published As

Publication number Publication date
US6653315B2 (en) 2003-11-25
JP4545437B2 (ja) 2010-09-15
EP1435960B1 (en) 2014-07-30
CA2463598A1 (en) 2003-04-24
AU2002340184B2 (en) 2005-10-06
JP2005506352A (ja) 2005-03-03
KR100687954B1 (ko) 2007-02-27
IL160878A0 (en) 2004-08-31
CN1612736A (zh) 2005-05-04
MY124864A (en) 2006-07-31
US20030171381A1 (en) 2003-09-11
HUP0401777A2 (hu) 2004-12-28
CN100421663C (zh) 2008-10-01
MXPA04003474A (es) 2004-07-30
HUP0401777A3 (en) 2008-06-30
CA2463598C (en) 2009-09-08
NZ531761A (en) 2005-10-28
ZA200402812B (en) 2005-04-25
JP2008297312A (ja) 2008-12-11
AR037243A1 (es) 2004-11-03
EP1435960A1 (en) 2004-07-14
WO2003032996A1 (en) 2003-04-24
KR20050035155A (ko) 2005-04-15

Similar Documents

Publication Publication Date Title
PE20030477A1 (es) ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
PE20020062A1 (es) 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a
PE20030665A1 (es) ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
PE20081192A1 (es) Tratamiento del dolor
PE20120172A1 (es) Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide
PE20030975A1 (es) 2-(PIRIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONAS
PE20060185A1 (es) ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
PE20030415A1 (es) Derivados policiclicos de guanina como inhibidores de fosfodiesterasa v
AR030186A1 (es) Compuesto antibacteriano 3-aminoquinazolina-2,4-diona, composicion farmaceutica que lo comprende y su uso para fabricarla
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
PE20061424A1 (es) Compuestos triciclicos de base 1,6-dihidro-1-3,5,6-tetraaza-as-indaceno y composiciones farmaceuticas que comprenden los mismos
PE46899A1 (es) Derivados de n-fenil-sulfonamida
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20010964A1 (es) Derivados de tiazolilamida
PE20030431A1 (es) DERIVADOS QUINUCLIDINAS COMO AGONISTAS DEL RECEPTOR NICOTINICO DE LA ACETILCOLINA TIPO a7
PE20030808A1 (es) Derivados triciclicos heterociclicos como antagonistas receptores de trombina
PE20030653A1 (es) COMPUESTOS BICICLICOS[1,2,4]-TRIAZOL COMO ANTAGONISTAS DE RECEPTORES DE ADENOSINA A2a
PE20020470A1 (es) Derivados de pirazol como inhibidores de las enzimas proteina quinasas
PE20050141A1 (es) DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA
PE20030848A1 (es) Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1
PE20081844A1 (es) DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a
PE20070793A1 (es) Compuestos triciclicos que contienen nitrogeno como agentes antibacterianos
PE20100737A1 (es) Nuevos compuestos
PE20080744A1 (es) IMIDAZOL AMINAS COMO INHIBIDORES DE LA ß-SECRETASA

Legal Events

Date Code Title Description
FC Refusal